Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?  by Nishiyori, Atsushi et al.
Localization of fractalkine and CX3CR1 mRNAs in rat brain:
does fractalkine play a role in signaling from neuron to microglia?
Atsushi Nishiyoria, Masabumi Minamia, Yoshikazu Ohtania, Shinya Takamia,
Junki Yamamotoa, Nami Kawaguchia, Toshiaki Kumeb, Akinori Akaikeb, Masamichi Satoha;*
aDepartment of Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8304, Japan
bDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8304, Japan
Received 7 April 1998; revised version received 30 April 1998
Abstract Localization of the mRNAs for fractalkine, a CX3C
chemokine, and for its receptor CX3CR1 was investigated in the
rat brain. In situ hybridization study revealed that fractalkine
mRNA was dominantly expressed in neuronal cells particularly
in the olfactory bulb, cerebral cortex, hippocampus, caudate
putamen and nucleus accumbens. In vitro study using enriched
neuronal or glial culture supported the dominant expression of
fractalkine mRNA in neurons. On the other hand, CX3CR1
mRNA was dominantly expressed in glial cells throughout the
whole brain. The in vitro study suggested the cells expressing
CX3CR1 mRNA are microglia, not astrocytes or neurons.
Fractalkine appears to function as a signal molecule from neuron
to microglia.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Fractalkine is a novel protein belonging to the fourth class
of chemokines [1,2]. It is the only chemokine to possess a
CX3C motif in the chemokine domain as well as a mucin-
like domain. Membrane-bound and secreted forms of fractal-
kine have been reported [1], while no member of the C, CC or
CXC chemokine family has a membrane-bound form. [3,4].
Furthermore, the expression of fractalkine mRNA is hardly
detectable in T cells, B cells and mononuclear cells [1], where-
as abundant expression of C, CC and CXC chemokines is
observed in these cells [4^6]. Fractalkine is di¡erent from oth-
er chemokines also in the expression in the brain. Fractalkine
mRNA is constitutively expressed in the human [1] and mouse
[2] brain, while the expression of most other chemokines only
becomes detectable in the brain under certain pathological
conditions, such as in cases of ischemia, viral infection and
autoimmune disease [7^9].
Recently, the orphan receptor V28 was identi¢ed as the
receptor for fractalkine and renamed CX3C chemokine recep-
tor CX3CR1, which was reported to have seven putative
transmembrane helices characteristic to G protein-coupled re-
ceptors and to be expressed in leukocytes and mediate the
signals to control their migration and adhesion [10]. Further-
more, the rat orphan receptor RBS11 was shown to function
as the receptor for fractalkine in HEK293 cells and Xenopus
oocytes by Fra 2 assay and electrophysiological analyses [11].
The transcript for CX3CR1, as well as that for fractalkine, has
been shown to express in human [12] and rat [13] brains.
Constitutive expression of the mRNAs for both fractalkine
and its receptor, CX3CR1, in the central nervous system im-
plies that this chemokine has physiological roles there. Alter-
natively, since chemokines are known to be the molecules
which control tra⁄cking of immune cells to in£ammation
[14], fractalkine may play a critical role in the tra⁄cking of
neural cells in pathological conditions. Since this chemokine
has been shown to function as an adhesion molecule in vitro
[1,10], it may control cell-cell interactions in the brain. In the
present study, as a ¢rst step to elucidate the function of frac-
talkine in the central nervous system, we investigated the lo-
calization of fractalkine and CX3CR1 mRNAs in the rat
brain using an in situ hybridization technique. In addition,
to identify the cellular source(s) of these mRNAs, expression
of the mRNAs in enriched culture of neurons, astrocytes or
microglia was examined. The results revealed intense expres-
sion of fractalkine and CX3CR1 mRNAs in neurons and mi-
croglia, respectively, implicating fractalkine as a signal mole-
cule from neuron to microglia.
2. Materials and methods
2.1. Materials
Proteinase K was purchased from Merck (Darmstadt, Germany).
Salmon sperm DNA and ribonuclease A (RNase A) were from Sigma
(St. Louis, MO, USA). Yeast tRNA and dispase were from Boehr-
inger Mannheim (Mannheim, Germany). Eagle’s minimum essential
medium (MEM) was purchased from Nissui (Tokyo, Japan). All other
chemicals were from Nacalai Tesque (Kyoto, Japan).
2.2. cDNA cloning for rat fractalkine and CX3CR1
cDNAs for rat fractalkine and its receptor CX3CR1 were cloned
from whole brains of Sprague-Dawley rats which had been intraper-
itoneally injected with lipopolysaccharide (1 mg/kg). Total RNA was
extracted by a single step acid phenol/chloroform method using ISO-
GEN (Nippongene, Tokyo, Japan) and used as a template for syn-
thesis of the ¢rst-strand cDNA, where 20 Wg of total RNA was in-
cubated at 37‡C for 1 h with a mixture of 200 U/Wl of M-MLV reverse
transcriptase (Gibco BRL, Gaithersburg, USA), 1Ureverse transcrip-
tion bu¡er, 10 mM dithiothreitol (DTT), 1 unit/Wl RNasin, 10 ng/Wl
DNA random hexamers and 0.5 mM each of dATP, dGTP, dCTP
and dTTP in a volume of 60 Wl. An aliquot of the RT product was
added to 2 units of Taq DNA polymerase (Perkin-Elmer, Foster City,
CA, USA) and 20 pmol each of forward and reverse primers in 50 Wl
of Taq bu¡er containin-g 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
2 mM MgCl2, 0.1% Triton X100 and 0.2 mM each of dATP, dGTP,
dCTP and dTTP. The forward (5P-cctgtagctttgctcatccac-3P) and re-
verse (5P-cacgggcaccaggacatatga-3P) primers for fractalkine cDNA
and the forward ((5P-agctgctcaggacctcaccat-3P) and reverse (5P-gtca-
tatgcaggaactctggg-3P) primers for CX3CR1 cDNA were designed on
the basis of the sequence of human fractalkine cDNA (GenBank,
U84487) and rat CX3CR1 cDNA, RBS11 (GenBank, U04808) respec-
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tively. The cDNAs were ampli¢ed by 35 cycles of polymerase chain
reaction (PCR). The ampli¢ed cDNAs were electrophoresed in 1.5%
agarose gel, puri¢ed by Gene Clean II kit (Bio-101, La Jolla, CA,
USA) and ligated to pCR2.1 (Invitrogen, San Diego, CA, USA) or
pCR-script-Amp (Stratagene, La Jolla, CA, USA) plasmid vector.
Fractalkine cDNA was subcloned to pBluescript plasmid vector (Stra-
tagene). Sequence analyses using Abi Prism dye terminator sequencing
ready reaction kit (Perkin-Elmer) con¢rmed that the obtained
CX3CR1 cDNA contained a full length, but the fractalkine cDNA
was only part of the coding region. The full length cDNA for rat
fractalkine was obtained by 5P- and 3P-RACE PCR using Marathon
cDNA ampli¢cation kit (Clontech, Palo Alto, CA, USA). The reverse
primer for 5P-RACE (5P-tcacaccggcaccaggacgtac-3P) and the forward
primer for 3P-RACE (5P-gacacctaggatcacctcggccaccagg-3P) were de-
signed on the basis of the sequence of the obtained partial cDNA
for rat fractalkine.
2.3. In situ hybridization histochemistry for fractalkine and
CX3CR1
mRNAs
Male Sprague-Dawley rats weighing 180^200 g were used. The
brains were rapidly removed and frozen in powdered dry ice. Sagittal
sections (16 Wm) were prepared in a cryostat, thaw-mounted onto
gelatin-coated slides and stored at 380‡C until in situ hybridization
was conducted. In situ hybridization was conducted as described pre-
viously [15]. 35S-Labeled antisense and sense RNA probes were syn-
thesized in the presence of [K-35S]UTP (30 TBq/mmol, Amersham,
Buckinghamshire, UK) using the linearized plasmids and T7 and T3
RNA polymerases (Promega, USA), respectively. Speci¢c activities of
35S-labeled probes were 1.0^1.2U109 cpm/Wg. After in situ hybridiza-
tion, the slides were exposed to an autoradiographic ¢lm, Hyper¢lm
Lmax (Amersham). After 10 days exposure, the ¢lm was developed
with D-19 (Kodak, New York, USA). Then, the slides were dipped in
autoradiographic emulsion NTB-3 (Kodak) diluted 1:1 with water.
After 3 weeks of exposure at 4‡C, they were developed with D-19
(Kodak) and counterstained with cresyl violet. Anatomical nomencla-
ture followed Paxinos and Watson [16].
2.4. Detection of fractalkine and CX3CR1 mRNAs in the brain and
enriched neuronal and glial cultures by RT-PCR
Sprague-Dawley rat brains were used for neuronal and glial cul-
tures. The cultures were maintained at 37‡C in 5% CO2/95% air.
Neuronal culture was prepared from the cerebral cortex of fetal rats
(16^18 days gestation) as previously described [17]. The culture was
used for the extraction of total RNA after 10^14 days of cultivation.
Astrocyte culture was prepared from the cerebral cortex of neonatal
rats (1 day old) according to the method of Takuma et al. [18]. The
purity of astrocytes was s 90%, as determined by immunostaining
with anti-glial ¢brillary acidic protein antibody. Microglial culture
was prepared from whole brains of neonatal rats (1 or 2 days old)
according to the method of Suzumura et al. [19]. The purity of micro-
glia was s 98%, as determined by immunostaining with OX-42 anti-
body.
Total RNA was extracted from cultured cells or whole brains by a
single step acid phenol/chloroform method. 5 Wg of each total RNA
sample was used for the synthesis of the ¢rst-strand cDNA, then PCR
was carried out in 20 Wl of reaction mixture containing 0.25 Wl of RT
product. The conditions for the RT reaction and PCR were the same
as described above. The forward (5P-gaattcctggcgggtcagcacctcggcata-
3P) and reverse (5P-aagcttttacagggcagcggtctggtggt-3P) primers for rat
fractalkine cDNA and the forward (5P-agctgctcaggacctcaccat-3P) and
reverse (5P-gttgtggaggccctcatggctgat-3P) primers for rat CX3CR1
cDNA were designed on the basis of the sequence of rat fractalkine
cDNA, which was cloned and sequenced in the present study, and rat
CX3CR1 cDNA (GenBank, U04808), respectively. The cDNAs were
ampli¢ed by 35 cycles of PCR. Each cycle of PCR for both fractalkine
and CX3CR1 consisted of denaturation at 94‡C for 60 s, annealing
at 60‡C for 30 s and extension at 72‡C for 60 s. The PCR products
were electrophoresed in 3% agarose gel in TAE bu¡er, and then the
gel was stained with ethidium bromide and photographed. PCR
products were con¢rmed to be the partial cDNAs of fractalkine and
CX3CR1, respectively, by sequence analyses and restriction enzyme
digestion.
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Fig. 1. Deduced amino acid sequence of rat fractalkine compared with mouse and human counterparts. Amino acid residues conserved between
more than two species are shadowed. The predicted signal peptide is indicated by an underline, the conserved cysteine residues characteristic of
the chemokine superfamily by asterisks (*), and the putative transmembrane domain by a double underline. The dibasic motif (-Arg-Arg-) in
the extracellular juxtamembrane, a postulated enzymatic cleavage site, is conserved among the three species and shown by sharps (#).
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3. Results
3.1. Rat fractalkine cDNA
A partial cDNA (130^1174) of the coding region of rat
fractalkine was cloned from rat whole brain by a RT-PCR
method, and then the remains (317^129 and 1180^1224) were
cloned by 5P-RACE and 3P-RACE methods. Five dependent
clones were sequenced to avoid errors due to misincorpora-
tion by Taq DNA polymerase which lacks 3P-5P exonuclease
(proofreading) activity. The deduced amino acid sequence of
rat fractalkine was compared with that of mouse and human
fractalkine (Fig. 1). Rat fractalkine shares 84.6% and 66.1%
homology overall, 85.5% and 82.7% homology in the chemo-
kine domain, 79.9% and 53.9% homology in the mucin-like
domain, 100% and 100% homology in the transmembrane
domain, and 100% and 91.9% homology in the intracellular
region, with mouse and human counterparts, respectively. The
CX3C motif in the chemokine domain and the dibasic motif
(Thr-Arg-Arg-Gln) in the extracellular juxtamembrane are
conserved among these three species.
3.2. Expression of fractalkine mRNA in the rat brain
In situ hybridization study revealed that fractalkine
mRNA was expressed in various brain regions. Fractalkine
mRNA was expressed intensely in the olfactory bulb, cere-
bral cortex, hippocampus, caudate putamen and nucleus
accumbens, weakly in the hypothalamus and midbrain,
but scantly in the pons, medulla oblongata and cerebellum
(Fig. 2a). In white matter, such as corpus callosum, ex-
pression of the mRNA was not detected. Sense RNA probe
did not detect any signi¢cant signals in the adjacent section
(Fig. 2b). Microautoradiograms showed that the signals
were dominantly localized to the cells which had relatively
large and lightly counterstained nuclei, likely neuronal cells,
in all regions where fractalkine mRNA was expressed
(Fig. 2c).
3.3. Expression of CX3CR1 mRNA in the rat brain
CX3CR1 mRNA was expressed throughout the whole brain
almost uniformly (Fig. 2d). Di¡erent from fractalkine mRNA,
CX3CR1 mRNA was expressed in white matter as intensely as
in gray matter. Slightly more intense signals were observed in
the choroid plexus and substantia nigra. Sense RNA probe
did not detect any signi¢cant signals in the adjacent section
(Fig. 2e). Throughout the brain excluding the choroid plexus,
the signals for CX3CR1 mRNA localized to the cells which
had relatively small and densely counterstained nuclei, likely
glial cells (Fig. 2f).
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Fig. 2. Localizations of fractalkine (a) and CX3CR1 (d) mRNAs in the rat brain as visualized by in situ hybridization with 35S-labeled anti-
sense RNA probes. Sense RNA probes did not give signi¢cant signals (b, e). Microautordiograms for the expression of fractalkine (e) and
CX3CR1 (f) mRNAs in the cerebral cortex. Fractalkine mRNA was localized to the cells which had relatively large and lightly counterstained
nuclei, likely neuronal cells, shown by arrows (c). On the other hand, CX3CR1 mRNA was expressed in the cells which had relatively small
and densely counterstained nuclei, likely glial cells, shown by arrowheads (f). AOV, anterior olfactory nucleus; Cx, cerebral cortex; CA1, CA1
part of the Ammon’s horn; CA3, CA3 part of the Ammon’s horn; CPu, caudate putamen; DG, dentate gyrus; Th, thalamus; Ce, cerebellum;
SN, substatia nigra; LV, lateral ventricle; LR4V, lateral recess 4th ventricle. Bar = 5 mm in a, b, d and e, and 25 Wm in c and f.
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3.4. Expression of fractalkine and CX3CR1 mRNAs in
enriched neuronal and glial cultures
To clarify which types of cell express fractalkine and
CX3CR1 mRNAs, the expression of these mRNAs in en-
riched neuronal and glial cultures was investigated by a RT-
PCR method. RT-PCR with the samples from whole brain,
which had been shown to contain both fractalkine and
CX3CR1 mRNAs by in situ hybridization, gave a signi¢cant
single band for each mRNA with the predicted mobility in
ethidium bromide-stained agarose gel. Primary cerebral cort-
ical neurons as well as whole brain intensely expressed frac-
talkine mRNA (Fig. 3a). In addition, fractalkine mRNA was
weakly expressed in microglia and astrocyte cultures. On the
other hand, CX3CR1 mRNA was expressed dominantly in
microglia (Fig. 3b), though the expression was not detected
in cerebral cortical neurons and astrocytes.
4. Discussion
In this study, we isolated rat fractalkine cDNA and deter-
mined its nucleotide sequence. The deduced amino acid se-
quence of rat fractalkine shared 84.6% and 66.1% identity
overall with human and mouse counterparts, respectively.
Higher homology was observed in the chemokine domain.
The amino acid sequences in the transmembrane and intra-
cellular domain were almost completely conserved among
these three species. The dibasic motif (Thr-Arg-Arg-Gln) in
the extracellular juxtamembrane was conserved, suggesting
that rat fractalkine is also released by enzymatic cleavage at
this site [20].
Next, we elucidated the localization of the mRNAs for
fractalkine and its receptor CX3CR1 in the rat brain. Frac-
talkine mRNA was constitutively expressed in normal rat
brain. Fractalkine mRNA was expressed intensely in most
parts of the telencephalon and some parts of the diencepha-
lon, but only weakly or scantly in the rest of the brain. No
signals for fractalkine mRNA were observed in white matter.
The signals were shown to be localized to cells which had
relatively large nuclei counterstained lightly by cresyl violet.
These ¢ndings suggest that fractalkine mRNA is expressed in
neurons. This idea is supported by the experiments using en-
riched neuronal and glial cultures, which showed that fractal-
kine mRNA was expressed intensely in cerebral cortical neu-
rons, but very weakly in enriched microglia and astrocyte
cultures. These characteristics of the expression of fractalkine
mRNA in the brain are unique, because the mRNAs for most
members of the C, CC or CXC chemokine family cannot be
detected in normal brain. Furthermore, although the mRNAs
for some CC and CXC chemokines are reported to be ex-
pressed inducibly in the brains under certain pathological con-
ditions, in such cases the mRNAs are expressed dominantly in
glial cells, not in neurons [7^9]. Fractalkine mRNA was ex-
pressed very weakly or scantly in the pons, medulla oblongata
and cerebellum, while CX3CR1 mRNA was expressed in these
brain regions as intensely as in other regions, such as the
cerebral cortex, hippocampus and caudate putamen. These
¢ndings suggest a possibility that other CX3C chemokines
than fractalkine are expressed in the brain. This possibility
is seemed to be likely, since most CCR- and CXCR-type
chemokine receptors are known to have two or more chemo-
kines as their ligands.
CX3CR1 mRNA was expressed throughout the whole brain
almost uniformly. Also, it was expressed in white matter as
intensely as in gray matter. The signals for CX3CR1 mRNA
were localized to the cells which had relatively small nuclei
counterstained densely by cresyl violet. These ¢ndings suggest
that CX3CR1 mRNA is expressed in glial cells rather than
neurons. The results from the experiments using enriched neu-
ronal and glial cultures indicate that the mRNA for this re-
ceptor is dominantly expressed in microglial cells. To con¢rm
the existence of functional CX3CR1 receptors exclusively in
microglia, not in neurons and astrocytes, we are currently
examining the e¡ects of fractalkine on intracellular Ca2 con-
centration in these cells. Microglia are reported to express a
FEBS 20348 15-6-98
Fig. 3. Detection of fractalkine (a) and CX3CR1 (b) mRNAs in the
brain and enriched neuronal and glial cultures by a RT-PCR meth-
od. The mobility of size markers is indicated on the right.
Fig. 4. Hypothetic roles of fractalkine as both a ‘chemotactic factor’
and an ‘adhesion molecule’ in the interaction between neuronal and
microglial cells. The secreted form of fractalkine released from neu-
rons may function as a chemotactic factor to cause the activation
and migration of microglial cells. On the other hand, fractalkine in
membrane-bound form could play a role as an ‘adhesion molecule’
in direct interaction between neuronal and microglial cells, such as
synaptic stripping, and be involved in synaptic reorganization in
normal and/or degenerated brains.
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variety of chemokine receptors, such as CCR3, CCR5,
CXCR4 [21,22], which are thought to mediate the signals in-
volved in the activation and/or migration of microglia.
CX3CR1 might also play a crucial role in regulating the acti-
vation and/or migration of microglia in the brain. In addition
to the brain parenchyma, CX3CR1 mRNA was expressed in
the choroid plexus. This result is interesting, when considering
that the choroid plexus is located at the boundary between
brain parenchyma and peripheral circulation. Further experi-
ments, including the identi¢cation of cell species, are necessary
to clarify the roles of CX3CR1 receptors expressed in the
choroid plexus.
The present study demonstrated that, unlike other chemo-
kines, fractalkine is constitutively expressed in neurons of
normal rat brain. Furthermore, its receptor has been shown
to be expressed dominantly in microglia. From these ¢ndings,
it is conceivable that fractalkine in the brain works as a mol-
ecule signaling from neuron to microglia. It is well known that
activated microglia are observed around degenerated neurons
in brains undergoing ischemia [23] and neurodegenerative dis-
ease, such as Alzheimer’s disease, Parkinson’s disease and
multiple sclerosis [24^26]. It has also been reported that ax-
otomy of the rat facial nerve leads to mitotic divisions of
microglial cells in the central nucleus of origin [27]. In those
cases, signal molecule(s) is thought to be released from the
degenerated or damaged neurons to inform microglia of their
state. Fractalkine might be released from neurons and func-
tion as a chemotactic factor to cause the activation and mi-
gration of microglial cells. In fact, in vitro experiments inves-
tigating the e¡ects of fractalkine on microglia revealed that it
was a potent chemoattractant for microglia [28]. Fractalkine
has a membrane-bound form besides a secreted form, while all
other chemokines exist as only a secreted form. Furthermore,
recently, this chemokine was shown to function as an adhe-
sion molecule [1,10]. Thus, fractalkine could play a role in the
cell-cell interaction which needs direct contact between neuro-
nal and microglial cells. One example of such an interaction,
in the rat facial nerve model, is ‘synaptic stripping’, whereby
microglia displace synaptic terminals from the surface of re-
generating neurons [27]. Since fractalkine is constitutively ex-
pressed in the brain, it may be involved in synaptic reorgan-
ization for regulating neuronal plasticity not only in
degenerated, but in normal brain. Fig. 4 schematically shows
the hypothetic roles of fractalkine as both a ‘chemotactic fac-
tor’ and an ‘adhesion molecule’ in the interaction between
neuronal and microglial cells.
Fractalkine immunoreactivity was found to be localized to
microglial and endothelial cells in the mouse brain by immu-
nohistochemistry with a polyclonal antibody against the syn-
thesized oligopeptide derived from the chemokine domain of
mouse fractalkine [2]. This ¢nding appears to be inconsistent
with our present demonstration that fractalkine mRNA was
dominantly expressed in neurons. There are several explana-
tions for this discrepancy. (1) A species di¡erence between
mouse and rat. (2) Fractalkine mRNA is translated into pro-
tein ine⁄ciently in neuronal cells, but e⁄ciently in microglia
where weak expression of fractalkine mRNA was detected by
a RT-PCR method. (3) In neuronal cells, fractalkine is re-
leased immediately after it is produced, since it is thought
that fractalkine in membrane-bound form can be enzymati-
cally cleaved to obtain the secreted form. In this case, it is
speculated that neurons always act on the surrounding micro-
glia through fractalkine in normal brain because its receptor is
constitutively expressed in microglia. Fractalkine immuno-
reactivity detected on microglia in mouse brains may be due
to the fact that fractalkine originally produced in neurons is
taken up by microglia by a certain mechanism, such as endo-
cytosis. (4) The chemokine domain of membrane-bound frac-
talkine expressed on neurons may be masked. This hypothesis
is attractive because it implies that the biological activity of
fractalkine is regulated by masking and unmasking in re-
sponse to the state of neuronal cells and/or the condition of
the extracellular microenvironment.
In this article, we propose that fractalkine plays a role in
the signaling from neuron to microglia in the brain. However,
it remains unclear how the synthesis and secretion of fractal-
kine are regulated and what the physiological and patholog-
ical roles of this chemokine in the brain are. As one way to
address these issues, we are now raising antibodies against the
respective domains of rat fractalkine, that is, the chemokine,
mucin-like, transmembrane and intracellular domains.
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